ATE266417T1 - Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien - Google Patents
Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagienInfo
- Publication number
- ATE266417T1 ATE266417T1 AT95940738T AT95940738T ATE266417T1 AT E266417 T1 ATE266417 T1 AT E266417T1 AT 95940738 T AT95940738 T AT 95940738T AT 95940738 T AT95940738 T AT 95940738T AT E266417 T1 ATE266417 T1 AT E266417T1
- Authority
- AT
- Austria
- Prior art keywords
- preventing
- treating vascular
- hemorrhagia
- medications
- alzheimer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9726—Tissue plasminogen activator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/347,144 US5589154A (en) | 1994-11-22 | 1994-11-22 | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
PCT/US1995/015007 WO1996015799A1 (en) | 1994-11-22 | 1995-11-22 | Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE266417T1 true ATE266417T1 (de) | 2004-05-15 |
Family
ID=23362515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95940738T ATE266417T1 (de) | 1994-11-22 | 1995-11-22 | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien |
Country Status (7)
Country | Link |
---|---|
US (1) | US5589154A (de) |
EP (1) | EP0792156B1 (de) |
JP (1) | JPH10509457A (de) |
AT (1) | ATE266417T1 (de) |
AU (1) | AU4239196A (de) |
DE (1) | DE69533040D1 (de) |
WO (1) | WO1996015799A1 (de) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19602295C2 (de) * | 1996-01-23 | 2003-08-14 | Deutsches Krebsforsch | Verwendung eines Konjugats aus einer zur Fluoreszenz-fähigen Verbindung, Cyanurchlorid oder einem Derivat davon als Linker und einem Protein |
US8173127B2 (en) * | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6214879B1 (en) * | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US6746841B1 (en) * | 1999-04-14 | 2004-06-08 | Whatman Inc. | FTA- coated media for use as a molecular diagnostic tool |
US20040146521A1 (en) * | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
US6689753B1 (en) * | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
ATE364689T1 (de) | 1999-11-18 | 2007-07-15 | Dendreon Corp | Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung |
US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
US7700341B2 (en) * | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
WO2001062284A2 (en) * | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Novel method for down-regulation of amyloid |
KR100879810B1 (ko) * | 2000-02-21 | 2009-01-22 | 하. 룬드벡 아크티에셀스카브 | 아밀로이드의 하향-조절을 위한 신규한 방법 |
JP2003516929A (ja) * | 2000-06-01 | 2003-05-20 | ニユーララブ・リミテツド | アミロイド形成性疾患の予防および治療 |
US7311893B2 (en) * | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
KR20040011480A (ko) | 2001-03-22 | 2004-02-05 | 덴드레온 샌 디에고 엘엘씨 | 세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
EP1379637A4 (de) | 2001-03-27 | 2005-04-06 | Dendreon Corp | Transmembran-serinprotease 9 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren |
AU2002258808A1 (en) * | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
WO2002088307A2 (en) * | 2001-04-30 | 2002-11-07 | Eli Lilly And Company | Humanized antibodies |
EP1539942A4 (de) | 2001-05-14 | 2005-10-19 | Dendreon Corp | Eine transmembran-serinprotease 10 codierende nukleinsäuremoleküle, die codierten polypeptide und darauf beruhende verfahren |
US20040248766A1 (en) * | 2001-06-18 | 2004-12-09 | Andrea Leblanc | Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons |
JP4178405B2 (ja) * | 2001-07-18 | 2008-11-12 | 小野薬品工業株式会社 | 脳虚血疾患治療剤 |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
EP1820806A1 (de) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinitätsbereiche |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
OA12055A (fr) * | 2002-04-05 | 2003-10-24 | Wandji Thomas Dr | Procédé d'extraction d'un nouveau composé à partirde la racine d'une plante de la famille des penta diplandracées. |
JP2006502100A (ja) * | 2002-06-11 | 2006-01-19 | エーザイ株式会社 | 細胞の異常消失に関わる障害の治療のための、および/または、肥満の治療のためのgip活性を有する化合物の使用 |
EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US20060269630A1 (en) * | 2003-04-16 | 2006-11-30 | Palu Afa K | Morinda citrifolia as a 5-Lipoxygenase inhibitor |
US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
KR100543056B1 (ko) * | 2003-11-07 | 2006-01-20 | (주)네추럴에프앤피 | 신경세포 보호 활성이 있는 포도씨 추출물을 포함하는뇌질환 예방 및 치료용 조성물 |
US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
US7205145B2 (en) * | 2004-03-24 | 2007-04-17 | Zefon International, Inc. | Gas-borne matter collection device |
US20050266415A1 (en) * | 2004-05-28 | 2005-12-01 | Zefon International, Inc. | Method for sampling gas-borne matter |
EP2298807A3 (de) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung |
AU2005272396A1 (en) * | 2004-08-11 | 2006-02-16 | Mitsubishi Chemical Corporation | Antibody and utilization of the same |
TWI384069B (zh) * | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
TWI374935B (en) * | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
EP1838854B1 (de) | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antikörper, die Amyloid-Peptide erkennen |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
US20060216363A1 (en) * | 2005-03-28 | 2006-09-28 | Liu Su Y | Novel herbal composition |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
KR100776347B1 (ko) * | 2005-05-23 | 2007-11-29 | 동양물산기업 주식회사 | 신경세포 보호 활성이 있는 둥근마 추출물을 포함하는 뇌질환 예방 및 치료용 조성물 |
US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
CA2615028A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Cross-.beta. structure binding compounds |
EP1906995A2 (de) * | 2005-07-13 | 2008-04-09 | Crossbeta Biosciences B.V. | Adjuvation durch kreuzstruktur |
EP2428117A1 (de) * | 2005-08-18 | 2012-03-14 | Rutgers, The State University | Entzündungshemmende Wirkung von Phenethylisothiocyanat (PEITC) und die Barbarea-verna-Saatvorbereitung mit dieser Verbindung |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
MX2009000476A (es) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
US7926368B2 (en) * | 2006-11-01 | 2011-04-19 | Zefon International, Inc. | Humidity-controlled gas-borne matter collection device |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
PL2118300T3 (pl) * | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2149584B1 (de) * | 2007-04-20 | 2017-12-13 | The Chemo-Sero-Therapeutic Research Institute | Verfahren zur verstärkung der immunreaktion mit einem peptid |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US7731994B2 (en) * | 2007-06-13 | 2010-06-08 | Industry Academic Cooperation Foundation Of Kyunghee University | Pharmaceutical composition for protecting neurons comprising extract of lithospermum erythrothizon SIEB. ET. Zucc or acetylshikonin isolated therefrom as an effective ingredient |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
WO2009048539A2 (en) | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Monoclonal antibody |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
US20090258091A1 (en) * | 2008-04-09 | 2009-10-15 | Marine Bio Co., Ltd. | Compositions and methods for treating neurodegenerative diseases |
JP5474807B2 (ja) * | 2008-10-16 | 2014-04-16 | 一般財団法人化学及血清療法研究所 | 改変アミロイドβペプチド |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
AU2010258355B2 (en) * | 2009-06-12 | 2016-04-28 | Generex Pharmaceuticals, Inc. | Compositions and methods for prevention and treatment of coronary heart diseases |
KR101713365B1 (ko) | 2010-07-30 | 2017-03-08 | 에이씨 이뮨 에스.에이. | 안전하고 기능적인 인간화 항 베타-아밀로이드 항체 |
JP2012102131A (ja) * | 2012-01-05 | 2012-05-31 | Elan Pharma Internatl Ltd | アミロイド形成性疾患の予防および治療 |
WO2013172964A1 (en) * | 2012-05-18 | 2013-11-21 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
KR20180077819A (ko) * | 2016-12-29 | 2018-07-09 | 사회복지법인 삼성생명공익재단 | 뇌아밀로이드 혈관병증의 예후 예측방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231000A (en) * | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US5304482A (en) * | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
US5025032A (en) * | 1989-10-17 | 1991-06-18 | Oklahoma Medical Research Foundation | Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage |
US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
EP0527823A1 (de) * | 1990-04-24 | 1993-02-24 | The Regents Of The University Of California | Reinigung, nachweis und verfahren zur verwendung der protease-nexin-2 |
US5175253A (en) * | 1991-04-24 | 1992-12-29 | Washington University | Binding peptides |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5436153A (en) * | 1992-12-02 | 1995-07-25 | Sprecher; Cindy A. | Human amyloid protein precursor homolog and Kunitz-type inhibitor |
JPH0739374A (ja) * | 1993-07-28 | 1995-02-10 | Sumitomo Pharmaceut Co Ltd | 新規なt−PA改変体 |
-
1994
- 1994-11-22 US US08/347,144 patent/US5589154A/en not_active Expired - Fee Related
-
1995
- 1995-11-22 DE DE69533040T patent/DE69533040D1/de not_active Expired - Lifetime
- 1995-11-22 WO PCT/US1995/015007 patent/WO1996015799A1/en active IP Right Grant
- 1995-11-22 AU AU42391/96A patent/AU4239196A/en not_active Abandoned
- 1995-11-22 AT AT95940738T patent/ATE266417T1/de not_active IP Right Cessation
- 1995-11-22 JP JP8516997A patent/JPH10509457A/ja active Pending
- 1995-11-22 EP EP95940738A patent/EP0792156B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5589154A (en) | 1996-12-31 |
DE69533040D1 (de) | 2004-06-17 |
EP0792156A4 (de) | 2000-03-01 |
WO1996015799A1 (en) | 1996-05-30 |
JPH10509457A (ja) | 1998-09-14 |
AU4239196A (en) | 1996-06-17 |
EP0792156A1 (de) | 1997-09-03 |
EP0792156B1 (de) | 2004-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE266417T1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
DE69024039D1 (de) | Behandlung von pathologischen zuständen und krankheiten. | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
NO20092874L (no) | Forhindring og behandling av amyloidogen sykdom | |
DE3482754D1 (de) | Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung. | |
DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
DE69403969D1 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
DE58906239D1 (de) | Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn. | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE213163T1 (de) | Verfahren zur behandlung von motorischen defiziten | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
DE69014501T2 (de) | Verfahren zur Behandlung von Titanlegierung und damit hergestelltes Stück. | |
DE69630055D1 (de) | Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation | |
DE69821970D1 (de) | Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE | |
DE69307702T2 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
DE69428797T2 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
DE3280419T2 (de) | Medizinisches praeparat zur behandlung von hautleiden. | |
ATE336282T1 (de) | Katheter zur behandlung von prostaterkrankungen | |
DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen | |
DE69627137D1 (de) | Verwendung von pentosan polysulfat zur behandlung von narben in chronischer fortschreitender gefässerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |